Worth reading
70In focus
Scored from 4 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
270000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance of Series 27 Stock Acquisition Rights through a third-party allotment (with exercise price adjustment, mNAV, floor exercise price adjustment and exercise suspension provisions); this disclosure reports the monthly exercise status
Who receives how much
Shares delivered during the month under review: 270,000 new shares and 0 transferred treasury shares
EVO FUND (allottee of the 27th Series of Stock Acquisition Rights)
The lower thin line represents the existing number of shares to which these shares will be added.
Existing Shares and Increase
+0.02%Rate of increase
1,274,171,340 shares1,281,283,624Shares
Exercise ratio subject to exercise restrictions: 0.02% (270,000 shares delivered across all series / 1,274,171,340 listed shares as of the payment date for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
8 May 2026: ¥362. The exercise price is adjusted on each trading day. The specific amount of the floor exercise price is Not disclosed
Number of Stock Acquisition Rights
Total issued: 1,000,000 rights; exercised during the month under review: 2,700 rights; unexercised at the end of the preceding month: 950,000 rights; unexercised at the end of the month under review: 947,300 rights
Basis for determining the amount to be paid
The exercise price was first adjusted on 17 April 2026 and has since been adjusted on each trading day to the closing price on the immediately preceding trading day, or to the floor exercise price if that closing price is below the floor exercise price
Procedures under the Corporate Code of Conduct
Reported compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
1 April 2026 issuance: Series 27 Stock Acquisition Rights allotted to EVO FUND (issue price and total amount: Not disclosed)
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of Series 27 Stock Acquisition Rights through a third-party allotment (with exercise price adjustment, mNAV, floor exercise price adjustment and exercise suspension provisions); this disclosure reports the monthly exercise status |
| Number of shares to be issued or disposed of | Shares delivered during the month under review: 270,000 new shares and 0 transferred treasury shares |
| Intended allottee | EVO FUND (allottee of the 27th Series of Stock Acquisition Rights) |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 0.02% (270,000 shares delivered across all series / 1,274,171,340 listed shares as of the payment date for the issuance) |
| Total number of issued shares | 1,274,171,340 shares (number of listed shares as of the payment date for the issuance) → 1,281,283,624 shares (issued common shares as of 31 May 2026) |
| Basis for determining the amount to be paid | The exercise price was first adjusted on 17 April 2026 and has since been adjusted on each trading day to the closing price on the immediately preceding trading day, or to the floor exercise price if that closing price is below the floor exercise price |
| Exercise price | 8 May 2026: ¥362. The exercise price is adjusted on each trading day. The specific amount of the floor exercise price is Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 1,000,000 rights; exercised during the month under review: 2,700 rights; unexercised at the end of the preceding month: 950,000 rights; unexercised at the end of the month under review: 947,300 rights |
| Procedures under the Corporate Code of Conduct | Reported compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | 1 April 2026 issuance: Series 27 Stock Acquisition Rights allotted to EVO FUND (issue price and total amount: Not disclosed) |
Items this document does not state (18)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status of the Series 27 Stock Acquisition Rights in May 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.